JPMorgan analyst Jessica Fye raised the firm’s price target on BeOne Medicines (ONC) to $321 from $317 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene’s Robust Oncology Pipeline and Strategic Developments Justify Buy Rating with $300 Price Target
- Beigene’s Promising Phase 1 Study on BGB-21447 for Metastatic Breast Cancer
- BeiGene’s Zanubrutinib Study: A Potential Game-Changer for B-Cell Lymphoma Treatment
- Beigene’s Zanubrutinib Study: A Potential Game-Changer in Nephropathy Treatment?
- BeiGene’s Promising Phase 3 Study on Lung Cancer Treatment